Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification-Reference-Cited by-同舟云学术

Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification

Published:2014-02 Issue:2 Volume:20 Page:222-228
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Costa Luciano J.,Nista Elizabeth J.,Buadi Francis K.^ORCID,Lacy Martha Q.,Dispenzieri Angela,Kramer Cindy P.^ORCID,Edwards Kathy H.,Kang Yubin,Gertz Morie A.,Stuart Robert K.,Kumar Shaji

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference31 articles.

1. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

3. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial;Palumbo;Blood,2004

4. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe;Fermand;J Clin Oncol,2005

5. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma;Raje;Br J Cancer,1997

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma;Bone Marrow Transplantation;2023-09-04

2. Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors;Transplantation and Cellular Therapy;2023-06

3. Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices;PLOS ONE;2023-03-31

4. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials;Transplantation and Cellular Therapy;2023-03

5. Plerixafor use in New Zealand 2016‐2019: An Observational Study;Internal Medicine Journal;2022-05-13